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Abstract
Integrins are essential protagonists of the complex multi-step process of angiogenesis that has now become a major target
for the development of anticancer therapies. We recently reported and characterized that MVL-PLA2, a novel phospholipase
A2 from Macrovipera lebetina venom, exhibited anti-integrin activity. In this study, we show that MVL-PLA2 also displays
potent anti-angiogenic properties. This phospholipase A2 inhibited adhesion and migration of human microvascular-
endothelial cells (HMEC-1) in a dose-dependent manner without being cytotoxic. Using MatrigelTM and chick chorioallantoic
membrane assays, we demonstrated that MVL-PLA2, as well as its catalytically inactivated form, significantly inhibited
angiogenesis both in vitro and in vivo. We have also found that the actin cytoskeleton and the distribution of avb3 integrin,
a critical regulator of angiogenesis and a major component of focal adhesions, were disturbed after MVL-PLA2 treatment. In
order to further investigate the mechanism of action of this protein on endothelial cells, we analyzed the dynamic instability
behavior of microtubules in living endothelial cells. Interestingly, we showed that MVL-PLA2 significantly increased
microtubule dynamicity in HMEC-1 cells by 40%. We propose that the enhancement of microtubule dynamics may explain
the alterations in the formation of focal adhesions, leading to inhibition of cell adhesion and migration.
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Introduction
It is now well established that angiogenesis plays a critical role in
tumor growth and spread [1,2]. Tumor angiogenesis is a multistep
process characterized by the chemotactic and mitogenic response
of vascular endothelial cells to angiogenic growth factors,
proteolytic degradation of extracellular matrix (ECM) and
modulation of endothelial cell interactions with ECM components.
Each of these steps may represent a potential target for the
development of anti-angiogenic and anti-metastatic therapies [3].
During the angiogenic process, vascular cells become activated,
resulting in the acquisition of an invasive phenotype. This invasive
phenotype facilitates new vessel formation by promoting loosening
of cell-cell interactions, migration and invasion of the local
interstitium. Endothelial cell interactions with remodeled intersti-
tial components then lead to morphogenesis and cellular
reorganization into capillary structures. Several studies have
suggested crucial roles for integrin signaling in the regulation of
capillary tube formation, thus, expanding the mechanisms by
which integrins regulate angiogenesis (for review see [3]).
Integrins are a family of heterodimeric transmembrane
receptors that mediate cell-cell and cell-ECM interactions. These
cell adhesion molecules are composed by the non-covalent
association of a and b subunits. Although 18 a and 8 b subunits
have been described, only 24 different combinations have been
identified to date (reviewed in [4,5]). Interactions between
integrins and their ligands have been linked to many cellular
processes including adhesion, migration, proliferation, differenti-
ation, apoptosis and angiogenesis. An array of integrins has been
particularly implicated in the control of angiogenesis including
a1b1, a2b1, a3b1, a4b1, a5b1, a6b4, avb3 and avb5 [3,6].
Given the importance of integrin signaling in the regulation of
angiogenesis, indirect targeting of integrin function may represent
a clinically useful approach for controlling aberrant neovascular-
ization such as tumor angiogenesis. The study of the role played by
integrins during angiogenesis has been mainly focused on avb3.
This integrin interacts with several ECM proteins, such as
vitronectin, fibrinogen, fibronectin, thrombin, thrombospondin
and von Willebrand factor, and cooperates with molecules
endowed with different biological functions, including metallopro-
teases, growth factors and their receptors. Due to its numerous
functions and to its relatively limited cellular distribution, avb3
integrin represents an attractive target for therapeutic intervention
[6].
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Migration can be viewed as a periodically repeating sequence of
events that includes formation of pseudopodial protrusions at the
cell front, attachment and translocation of the cell body. Cell
migration thus depends on the continuous coordinated formation
and disassembly of actin-based adhesions (for review see [7]). The
assembly of new focal adhesions at the leading edge is necessary
for the formation of the lamellipodium and the initiation of
locomotion. This assembly is due to the clustering of integrins
upon their engagement with ECM components and to the
subsequent recruitment of scaffolding and signaling proteins [8].
Adhesion complexes thus mechanically link the ECM to the
cytoskeleton, but a concerted interaction of microtubules (MTs)
and actin is essential for maintaining cell motility [9,10]. Dynamic
instability of MTs is thus required to keep the polarized actin
cytoskeleton-based protrusions in the cell-leading edge [8].
Moreover, MTs promote the release of adhesion substrates by
targeting adhesion complexes at the cell front and rear with
different frequencies [11].
Snake venom is a natural source for molecules known as
modulators of integrin-mediated functions. These proteins belong
to two families, disintegrins and C-type lectin proteins (CLPs).
Since their initial characterization, snake venom disintegrins have
been extensively studied. They are potent and specific antagonists
of several integrins, such as avb3 and a5b1, and can thus act on
many biological processes including platelet aggregation, angio-
genesis, tumor invasion and bone destruction [12,13,14,15]. On
the other hand, CLPs were first described as modulators of platelet
aggregation before their anti-adhesive activity was highlighted.
CLPs are thus able to inhibit integrin-dependent proliferation,
migration, invasion and angiogenesis [16,17,18].
Snake venom type A2 phospholipases (PLA2s) (EC 3.1.1.4) are
quite fascinating from both a biological and structural point of
view. Despite their structure being conserved, they exhibit a wide
range of pharmacological activities [19]. In a previous work, we
showed for the first time that snake venom PLA2s inhibit adhesion
and migration of tumor cells [20,21]. We also demonstrated that
these effects were not mediated by the phospholipase catalytic
activity of MVL-PLA2 but through the inhibition of a5b1 and av
integrins [20]. However, to our knowledge, nothing is yet known
about the potential effects of snake venom PLA2 on angiogenesis.
In the present study, we investigated the impact of integrin
inhibition by MVL-PLA2, isolated from Macrovipera lebetina venom,
on vascular endothelial cells behavior. Our results reveal that
MVL-PLA2 inhibits endothelial cell adhesion and migration and
abolishes angiogenesis both in vitro and in vivo. Interestingly, we also
show that MVL-PLA2 enhances microtubule dynamics likely
leading to the alterations in the formation of focal adhesions,
which may explain its effect on angiogenesis.
Materials and Methods
MVL-PLA2 purification and enzymatic inactivation
The MVL-PLA2 was purified and its phospholipase catalytic
activity was inactivated by p-bromophenacyl bromide (BPB)
alkylation as described in a previous work [20].
Cell culture
HMEC-1 cells [22] were routinely maintained at 37uC and 5%
CO2 in MCDB-131 medium (Lonza, Levallois-Perret, France)
containing 10% heat-inactivated fetal bovine serum, 2 mmol/l
glutamine, 1% penicillin and streptomycin (all from Life
Technologies, Paisley, UK), 1 mg/ml hydrocortisone (Pharmacia
& Upjohn, St-Quentin-Yvelines, France) and 10 ng/ml epithelial
growth factor (R&D Systems, Minneapolis, MN). HMEC-1 cells
were grown on 0.1% gelatin-coated flasks and were used between
passages 3 and 12.
Cell adhesion and migration assays
Adhesion assays were performed as previously described [23].
Briefly, 96-well plates were coated with purified ECM protein
solutions or with MVL-PLA2 for 2 h at 37uC and blocked with
0.5% PBS/BSA. Cells in single cell suspension were added to wells
and allowed to adhere to the substrata for 1 h at 37uC. After
washing, adherent cells were fixed with 1% glutaraldehyde,
stained with 0.1% crystal violet and lysed with 1% SDS.
Absorbance was then measured at 600 nm. For adhesion assay
on antibodies, 96-well plates were coated with 50 ml of rabbit anti-
rat IgG (50 mg/ml), overnight at 4uC. Wells were washed once
with PBS and 50 ml of anti-integrin blocking antibodies (10 mg/ml)
were added for 5 h at 37uC. Then, wells were blocked with 0.5%
PBS/BSA and adhesion assay was continued as above.
In vitro cell migration assays were performed in modified Boyden
chambers (NeuroProbe Inc., Bethesda, MD) with porous mem-
branes pre-coated with 10 mg/ml of fibronectin or 50 mg/ml
fibrinogen for 5 h at 37uC as previously described [18].
In vitro capillary network formation on MatrigelTM
250 ml of 5.25 mg/ml MatrigelTM (BD Biosciences, Pont de
Claix, France) were added to 24-well plates and allowed to solidify
for 1 h at 37uC. HMEC-1 cells were harvested, added to each well
and incubated for 5 h at 37uC and 5% CO2. Cells were fixed with
4% formaldehyde and photographed using a DM-IRBE micro-
scope (Leica, Rueil-Malmaison, France) coupled with a digital
camera (CCD camera coolsnap FX, Princeton Instruments,
Trenton, NJ). The formation of capillary networks was quantita-
tively evaluated by measuring the total capillary tube length in 20
view fields per well using Metaview software as previously
described [24].
Cytotoxicity assay
The cytotoxicity of MVL-PLA2 was determined by measuring
the release of lactate dehydrogenase (LDH) activity into the
medium. Suspended HMEC-1 cells were preincubated for 30 min
at room temperature with MVL-PLA2 in DMEM containing
0.2% BSA and then added to MatrigelTM in 96-well plates
(100 ml/well) for 5 h at 37uC. Total release of LDH (100%
toxicity) was obtained by adding 0.1% Triton-X100 in incubation
medium. The supernatants were collected, clarified by centrifu-
gation 5 min at 600 g and 80 ml were submitted to LDH-based
cytotoxicity kit (Sigma).
Chick chorioallantoic membrane (CAM) angiogenesis
assay
The assay was performed as previously described [13,16]. In
brief, the CAMs were prepared using 8-day-old chick embryos.
Filter disks (Ø 6 mm) were soaked in 0.9% NaCl alone (control) or
containing various concentrations of MVL-PLA2. After 48 h
incubation, the discs were removed and the CAMs were
photographed with a digital camera at 610 magnification. To
quantify CAM angiogenesis, we counted the number of vessel
branching points per photographic field of the treated area using
ImageJ software.
Transfection of HMEC-1 with GFP-tagged a tubulin
plasmid
The transfection of HMEC-1 was done as previously described
[22]. In brief, 86105 HMEC-1 cells were transfected with 8 mg
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plasmid pEGFP-Tub (Clontech, Palo Alto, CA) encoding a fusion
protein consisting of the human codon-optimized variant of green
fluorescent protein (GFP) and the human a-tubulin gene, using
transfection buffer solution R and program T-16 of a Nucleo-
fectorH (Amaxa, Cologne, Germany). DNA quantity, cell concen-
tration, and buffer volume were kept constant throughout all
experiments. After transfection, cells were immediately transferred
into RPMI medium (Life Technologies) containing 10% heat-
inactivated fetal bovine serum, 2 mmol/l glutamine, 1% penicillin
and streptomycin, 1 mg/ml hydrocortisone, and 10 ng/ml epithe-
lial growth factor. Cells were seeded in six-well plates onto slides
pre-coated with 10 mg/ml fibronectin. Twenty-four hours later,
cells were incubated for 1 h in the presence or absence of MVL-
PLA2 or BPB-alkylated MVL-PLA2 and MT dynamics measure-
ments were performed.
Time-lapse microscopy and analysis of microtubule
dynamic instability
Measurement of MT dynamic instability in living HMEC-1
cells was performed as previously described [22]. Briefly,
transfected HMEC-1 cells were placed in RPMI culture medium
lacking sodium bicarbonate and supplemented with 25 mmol/L
HEPES, 4.5 g/l glucose and 3% (v/v) Oxyrase (Oxyrase, Inc.,
Mansfield, OH) to reduce photodamage. They were then placed
in a double coverslip chamber maintained at 3761uC and
observed using the6100 objective lens of an inverted fluorescence
microscope (Leica). Thirty-one images per cell were acquired at 4-
second intervals (see Video S1 and Video S2) using a digital
camera driven by Metamorph software (Universal Imaging
Corporation, Downingtown, PA) as previously described [22].
Analysis of MTs dynamics was done as described previously
using the track point function of the Metamorph software [25].
Changes in length $0.5 mm were considered as growth or
shortening events whereas changes in length ,0.5 mm were
considered as phases of attenuated dynamics or pauses. The rates
of growth and shortening events were determined by linear
regression. Means and SE were calculated per event. The
catastrophe frequency based on time was calculated by dividing
the number of transitions from growth or pause to shortening by
the total time growing and paused for each individual MT. The
rescue frequency based on time was inversely calculated, dividing
the total number of transitions from shortening to pause or growth
by the time spent shortening for each individual MT. Means and
SE of transition frequencies were calculated per MT (n.30, for
each experimental condition from three independent experi-
ments). Dynamicity is the total length grown and shortened
divided by the life span of MT population.
Fluorescence staining
Cells were grown on slides coated with 10 mg/ml fibronectin
and incubated for 48 h. Cells were incubated for 1 h in the
absence (control cells) or presence of MVL-PLA2 (100 nM), fixed
with formaldehyde 3.7% (15 minutes) and permeabilized with
0.1% saponin (30 minutes). Actin network was stained using
TRITC-conjugated phalloidin (1/4000). Integrin avb3 was
stained using LM609 antibody (1:500, Chemicon) and Alexa
fluor-488 conjugated secondary antibody (1:2000).
Statistical Analysis
All values are expressed as mean 6 standard deviation (SD).
The statistical significance of differential finding between exper-
imental and control groups was determined by Student’s t test
using GraphPad Prism 4 software. P,0.05 was considered
statistically significant and is indicated with asterisks over the
value (*: p,0.05; **: p,0.01; ***: p,0.001).
Results
MVL-PLA2 inhibits endothelial cell adhesion and
migration by blocking the adhesive function of a5b1 and
avb3 integrins
We recently purified and characterized a novel snake venom
PLA2, named MVL-PLA2 that impairs cell adhesion mediated by
a5b1 and av integrins in human cancer cell lines [20]. Given the
key role of a5b1 and avb3 in angiogenesis [3,26,27], we decided to
further evaluate the capacity of MVL-PLA2 to exert an anti-
angiogenic activity. First, we investigated the cytotoxicity of MVL-
PLA2 towards the human microvascular endothelial cell line-1
(HMEC-1). We have previously demonstrated that MVL-PLA2
was not cytotoxic toward human fibrosarcoma (HT1080) and
melanoma (IGR39) cell lines [20]. Using the MTT assay, we
found in the present study that MVL-PLA2 did not either
significantly affect the viability of HMEC-1 cells when incubated
for 3 days with protein concentrations up to 250 nM. We only
noted a slight decrease in the number of living cells for higher
concentrations (supplementary Fig. S1A), which could be due to
the inhibition of cell growth. Whatever the concentration tested,
neither did MVLPLA2 induce membrane damage after short term
times (mimicking the pre-incubation step (30 min. in suspension),
as visualized by the release of LDH (supplementary Fig. S1B).
In order to investigate whether MVL-PLA2 could inhibit
endothelial cell adhesion by impairing cell/ECM interactions
through an integrin-dependent mechanism, we measured the
effect of various concentrations of MVL-PLA2 against HMEC-1
cell adhesion to fibronectin (Fn) and fibrinogen (Fg). As shown in
Fig. 1A, MVL-PLA2 inhibited the adhesion of HMEC-1 cells to
both matrices. This inhibition was dose-dependent, with half-
maximal inhibition at a concentration (IC50) of about 170 nM and
250 nM for Fn and Fg, respectively (Fig. 1A). To determine which
integrins are involved in the attachment of endothelial cells to Fn
and Fg, we performed adhesion assays using function-blocking
anti-a5b1 and anti-avb3 antibodies. As shown in Fig. 1B, anti-
a5b1 antibody decreased HMEC-1 cells adhesion to Fn by 70%
and anti-avb3 decreased adhesion to Fg by 95%. Since a5b1 and
avb3 are both Arg-Gly-Asn (RGD)-dependent integrins, we tested
the ability of HMEC-1 cells to adhere onto immobilized MVL-
PLA2 in the presence of RGD peptides. As shown in Fig. 1C, we
observed that the adhesion of HMEC-1 cells treated with RGD
peptide was decreased by about 65% compared to untreated
HMEC-1 cells. Altogether these results above suggest that MVL-
PLA2 could interact with a5b1 and avb3 integrins in endothelial
cells. To address this issue, HMEC-1 cells were treated with MVL-
PLA2 for 30 min and allowed to adhere on various anti-integrin
antibodies. At 1 mM, MVL-PLA2 did not affect HMEC-1 cell
adhesion on anti-b1 integrin antibody (Fig. 1D). However, MVL-
PLA2 reduced HMEC-1 adhesion by 35% and 21% on anti-a5b1
and anti-avb3 integrins antibodies, respectively. It is thus likely
that the PLA2 inhibits the adhesive functions of a5b1 and avb3
integrins in vascular endothelial cells as previously reported for
tumor cells [20].
Cell migration can be considered as a finely regulated process
including successive steps of cell adhesion and de-adhesion.
Because MVL-PLA2 inhibits HMEC-1 cell adhesion, we also
examined its effect on cell migration using a haptotaxis assay in
modified Boyden chambers. MVL-PLA2 at 250 nM completely
blocked HMEC-1 cell migration towards Fn or Fg (Fig. 1E). This
inhibition was dose-dependent with IC50 of 30 nM and 70 nM for
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Fn and Fg, respectively. To know whether the treatment above
could affect cell integrity, suspended HMEC-1 cells were
incubated with various concentrations of MVL-PLA2 for
30 min. at room temperature and then plated on MatrigelTM in
the presence of the enzyme for 5h at 37uC. As illustrated in Fig. 1F,
the plasma membrane integrity, visualized by LDH release, was
not affected by incubation in the presence of MVL-PLA2 up to
1 mM.
Figure 1. MVL-PLA2 inhibits endothelial cell adhesion and migration through a5b1 and avb3 integrins. (A) HMEC-1 cells were pre-
incubated with various concentrations of MVL-PLA2 for 30 min at room temperature. Cells were then added along with the enzyme to 96-well
microtiter plates coated with 10 mg/ml fibronectin (Fn, closed triangles) or 50 mg/ml fibrinogen (Fg, open squares) and allowed to adhere for 1 h
at 37uC. After washing, adherent cells were stained with crystal violet, solubilized by SDS and absorbance was measured at 600 nm. Data shown
are means (6SD) of at least three independent experiments and expressed as a percentage of adhesion in the absence of PLA2. (B) Adhesion of
HMEC-1 cells, treated for 30 min at room temperature with 10 mg/ml antibodies against a5b1 (JBS5) or avb3 (LM609) integrins, was evaluated
on fibronectin or fibrinogen, respectively. Adhesion was measured as described above. Data shown are means (6SD) of at least three
independent experiments and expressed as a percentage of adhesion in the absence of antibody. (C) HMEC-1 cells, incubated without (2) or
with 1 mM GRGDSP peptide (RGD), were tested for adhesion on microtiter plates coated with 1 mM MVL-PLA2. (D) HMEC-1 cells were treated
without (open bars) or with (filled bars) 1 mM MVL-PLA2 and tested for adhesion on microtiter plates coated with antibodies raised against the
indicated integrin as described in the experimental section. (E) HMEC-1 cells, treated with various concentrations of MVL-PLA2, were allowed to
migrate for 5 h to fibronectin (Fn, closed triangles) or fibrinogen (Fg, open squares). Data shown (6S.D.) are expressed as a percentage of
migration in the absence of peptide. (F) Suspended HMEC-1 cells (0.56106 cells/ml) were preincubated for 30 min at room temperature with
various concentrations of MVL-PLA2 and then added along with the enzyme to MatrigelTM in 96-well plates (100 ml/well). Upon 5 h at 37uC, 80 ml
of clarified supernatant were submitted to LDH activity released by damaged cells using a colorimetric assay. Total release of LDH (100%
toxicity) was obtained by adding 0.1% Triton-X100 in the assay medium (TX100). Data shown (6S.D.) are from a representative experiment of
three performed in triplicate.
doi:10.1371/journal.pone.0010124.g001
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MVL-PLA2 inhibits angiogenesis in vitro and in vivo
Cell adhesion and migration play a key role in the angiogenic
process. Because the formation of capillary-like structures on
MatrigelTM by HMEC-1 cells can be inhibited by specific anti-
a5b1 and anti-avb3 antibodies (Fig. 2C), we hypothesized that
PLA2-mediated impairment of HMEC-1 adhesion and migra-
tion could also affect endothelial cell morphogenesis. In vitro
angiogenesis assays were thus performed using HMEC-1 cells
treated with various concentrations of native MVL-PLA2 or with
MVL-PLA2 catalytically inactivated by incubation with p-
bromophenacyl bromide (BPB). As illustrated in Fig. 2A and
2B, the native MVL-PLA2 strongly inhibited in vitro angiogenesis
in a dose-dependent manner. The inhibitory effect was observed
for concentrations as low as 50 nM of peptide. In addition, we
did not observe any difference in angiogenesis inhibition when
the phospholipase activity of MVL-PLA2 was inactivated
(Fig. 2B).
To further confirm the potent anti-angiogenic properties of
MVL-PLA2, we performed in vivo angiogenesis using chick
chorioallantoic membrane (CAM) assays. As illustrated in Fig. 3A,
MVL-PLA2 induced a marked reduction in the number of new
capillaries and branching vessels in the CAM, without affecting the
preexisting vessels. Furthermore, the peripheral vessels (relative to
the position of the disc) grew centrifugally, avoiding the treated area,
where a decrease in the vascular density could be observed. No sign
of irritation or inflammation were observed. This effect was dose-
dependent and MVL-PLA2 at 200 nM, induced a reduction of
vasculature in the treated area by about 90% as compared to the
control untreated CAM (Fig. 3B).
MVL-PLA2 affects focal adhesion organization
Focal adhesions (FA) are specialized sites of cell attachment to
the ECM where integrins receptors, such as avb3, link the ECM to
the actin cytoskeleton, allowing traction stress to drive migration
[28]. To determine whether MVL-PLA2 treatment could affect
actin organization, we performed double staining of actin fibers
and avb3 integrin. As illustrated in Fig. 4A, avb3 integrin (green)
is concentrated in large dots over the ventral face of lamellipodia at
the end of actin stress fibers (red). These dots are also stained by an
antibody against paxillin, a component of FAs (see Supplemental
Fig S2). Treatment of HMEC-1 cells with 100 nMMVL-PLA2 for
1 h induced important changes in cell morphology. Treated cells
have a circular shape and actin stress fibers are thinner or absent,
with the actin mainly located at the cell periphery (Fig. 4B).
Moreover, treatment by MVL-PLA2 resulted in a drastic
reduction in the size of FAs and their redistribution all over the
ventral surface of cells (Supplemental Fig S2), consistent with a
decrease in avb3 integrin clustering and its absence from
lamellipodia (Fig. 4B). Therefore, it appears that the inhibition
of migration by MVL-PLA2 treatment is associated with
important reorganization of the actin cytoskeleton and FAs.
MVL-PLA2 increases microtubule dynamics in living
human endothelial cells
Endothelial cell migration is a complex process that requires an
extensive reorganization of the cytoskeleton (for review see [8]).
Recent studies have pointed out an important role of MTs and
coordinated MT/actin dynamics in regulating cell migration
[9,10]. The dynamic properties of MTs, key components of the
Figure 2. MVL-PLA2 blocks in vitro angiogenesis. (A) Representative visualization of tubulogenesis assay after pre-treatment of HMEC-1 cells
without (control) or with 50, 100 or 500 nM MVL-PLA2 for 30 min at room temperature. Cells were then added to MatrigelTM in the presence of the
enzyme and allowed to form capillary-like structures for 5 h at 37uC. Scale bar: 70 mm. (B) Dose-effect of native MVL-PLA2 or catalytically inactive
MVL-PLA2 (MVL-PLA2+BPB), at the indicated concentration, on tubulogenesis on MatrigelTM. Quantification of tubulogenesis was done as described
in experimental section. Data shown (6S.D.) are from at least 3 independent experiments. (C) Tubulogenesis on MatrigelTM was performed as above
in the presence of the indicated anti-integrin antibodies (10 mg/ml). Data shown (6SD) are from 3 independent experiments.
doi:10.1371/journal.pone.0010124.g002
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cytoskeleton, are highly regulated both spatially and temporally
and this regulation is crucial for cell migration (for review see
[29,30]). Thus, we postulated that MVL-PLA2 might inhibit
endothelial cell migration by affecting MT dynamics. To verify
this hypothesis, we analyzed the dynamic instability behavior of
MTs in living HMEC-1 after 1 h incubation with 100 nM of
native or BPB-inactivated MVL-PLA2.
Fig. 5A shows an image gallery of the lamellar region of a
control untreated HMEC-1 cell (top panels) and a HMEC-1 cell
incubated with 100 nM native MVL-PLA2 (bottom panels). In the
control cells, the MT plus ends alternated between phases of slow
growing, rapid shortening and prolonged pause state (a state of
attenuated dynamic instability). Interestingly, 100 nM of MVL-
PLA2 markedly increased MT dynamics in HMEC-1 cells (see
videos S1 and S2 in supplementary data). For example, the plus
end of the MT indicated by arrowheads in the bottom panel of
Fig. 5A shortened for a long distance in a short period of time (12
seconds). Fig. 5B shows the life history traces of the changes in
length of 3 individual MTs in the absence (control) or in the
presence of 100 nM MVL-PLA2. The life history traces of MTs in
cells incubated with MVL-PLA2 show extensive length changes as
compared to the MTs from control cells.
At least 30 individual MTs per condition were analyzed to
determine the dynamic instability parameters. The effects of
MVL-PLA2 on these various variables are presented in Table 1.
In control cells, the overall MT dynamicity was 3.0 mm/min with
a mean growth rate of 7.1260.29 mm/min, slower than their
mean shortening rate of 8.7960.38 mm/min. The mean growing
and shortening lengths were 1.0660.03 and 1.3260.05 mm,
respectively and MTs spent 63% of their time in a paused state,
neither growing nor shortening to a detectable extent. After 1 h
incubation with MVL-PLA2 (100 nM), the percentage of dynamic
MTs was significantly increased (from 58.5% in control cells to
78.1% in MVL-PLA2-treated cells) and the overall MT dynami-
city was increased by 40%. This increase in MT dynamicity
induced by MVL-PLA2 was due to an increase in both the growth
and shortening rates (+31% and +13%, respectively) and a
decrease in the duration of pauses (222%), leading to a decrease
in the percentage of time spent in pause (from 63.1% to 56.4%).
In addition, as shown in Table 1, no significant difference was
observed between the effect of the native form of MVL-PLA2 and
its catalytically inactivated form. Indeed, incubation of HMEC-1
cells with 100 nM BPB-inactivated MVL-PLA2 resulted in a
significant increase in the percentage of dynamic MTs (from
58.5% to 76.7%) and a 50% increase in overall MT dynamicity.
As for the native form of MVL-PLA2, the increase in MT
dynamicity induced by inactivated MVL-PLA2 was due to an
increase in the shortening rate (+43%) and a decrease in the mean
duration of pause (224%), resulting in a decrease in the
percentage of time spent in pause (from 63.1% to 53.4%). The
main difference between the two forms of MVL-PLA2 was the
lack of increase in the MT growth rate observed with the
catalytically inactivated MVL-PLA2 (Table 1). These results
further confirmed the dissociation between the enzymatic activity
of MVL-PLA2 and its anti-angiogenic properties.
Discussion
Angiogenesis is the formation of new capillaries from pre-
existing blood vessels. Since Folkman first formulated the
hypothesis that tumor growth was angiogenesis-dependent in
1971 [31], intensive research has been carried out to confirm this
theory. As a result, tumor-recruited microvascular endothelial cells
have become an important target in cancer therapy and a number
of anti-angiogenic factors are currently being tested in clinical
trials (for review see [32]). Some of these agents are known to show
anti-angiogenic and anti-tumor activity via their ability to interact
with distinct integrins expressed in angiogenic endothelial cells of
tumor vasculature [3]. Numerous anti-angiogenic components
targeting integrin receptors have been isolated from snake venom.
Among these peptides, the disintegrin family was the first to be
characterized and the most extensively studied [15]. More
recently, we demonstrated that snake venom-derived C-type
lectins, such as lebectin from Macrovipera lebetina venom, also
displayed anti-angiogenic properties [16]. In the present study, we
extend these findings to another snake venom family and reveal
the anti-angiogenic properties of a newly discovered snake venom
PLA2, MVL-PLA2. This is the first report describing this new
pharmacological effect of a snake venom PLA2 and delineating its
mechanism of action.
The present study was based on earlier observations showing a
potent inhibitory effect of MVL-PLA2 on tumor cell adhesion and
migration [20]. Our results showed that MVL-PLA2 specifically
targets a5b1 and av-containing integrins in tumor cells. Since
Figure 3. MVL-PLA2 inhibits in vivo angiogenesis. (A) Chicken
CAMs were untreated (control) or treated with 40, 140 or 200 nM MVL-
PLA2. White discontinued circles represent location of applied disks.
Black arrows show peripheral microvessels grown centrifugally. Shown
photographs are representative of 3 experiments performed in
triplicate. (B) Quantitative measurement of neovascularisation was
performed by counting the blood vessel branch points present within
the treated area defined by the filter disc. Data are expressed as a
percentage of control (in the absence of peptide) and are means of
three independent experiments performed using five different CAMs.
doi:10.1371/journal.pone.0010124.g003
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a5b1 and avb3 integrin receptors are key actors of tumor
angiogenesis (for review see [3,26,27]), we postulated that MVL-
PLA2 could have an anti-angiogenic potential. Interestingly, we
demonstrated here that MVL-PLA2 impairs adhesion and
migration of vascular endothelial cell, as well as in vitro and in
vivo angiogenesis. This anti-angiogenic activity is not likely to be
due to any cytotoxic effect of MVL-PLA2 on endothelial cells.
Indeed, whatever the concentration used, the venom PLA2 did not
induce any plasma membrane damage, as no release of LDH was
observed upon the preincubation step (see supplemental Fig S1B)
or upon plating for 5 h (see Fig. 1F). Moreover, proliferation of
HMEC-1 cells was not affected by MVL-PLA2 over a 3-day
period for concentrations affecting angiogenesis (see supplemental
Fig S1), cells did not detach from the substratum during this period
and no cell debris could be observed (data not shown).
Elsewhere, by inactivating the PLA2 enzymatic site, we
previously showed a clear dissociation of the anti-tumor effect of
MVL-PLA2 and its catalytic activity [20]. The same observation
was made in the present study for the anti-angiogenic activity of
MVL-PLA2. Hence, our findings strongly support the concept of
target model proposed by Kini et al. [19] to explain the
pharmacological effects of PLA2s. According to this model, high
affinity protein-protein interactions between PLA2 and membrane
protein in the target cells determine the specific pharmacological
effects of PLA2 enzymes.
Our results on tumor cells [20] and endothelial cells (this study)
suggest that MVL-PLA2 could interfere with a5b1 and avb3
integrins function. Angiogenesis involves de novo expression of the
integrin avb3, which binds to RGD-containing components of the
interstitial matrix [33]. Furthermore, a5b1 integrin is expressed in
growing vessels, but its expression disappears in mature vessels (for
a review see [34]). Consistent with this, our results showed that
MVL-PLA2 does not affect stable, established blood vessels on
CAMs, but strongly reduces the number of new capillaries and
vascular branching.
It is well established that RGD-containing peptides have anti-
angiogenic properties due in part to inhibition of av-dependent
adhesion and can prevent vascular lumen formation [35,36]. We
show here that endothelial cells are able to adhere on immobilized
MVL-PLA2 and that this adhesion is impaired by RGD peptides.
Similar results were obtained with tumor cells [20]. This suggests
that the interaction between MVL-PLA2 and integrins involves an
RGD-like sequence which may be responsible for the inhibition of
integrin function. MVL-PLA2 contains a NGD similar sequence
that may be responsible for the inhibition of integrin function.
Further structure-function relationships studies must be carried
out to verify this hypothesis.
Our findings clearly show that MVL-PLA2 efficiently abolishes
adhesion and migration of endothelial cells and capillary tube
formation. These processes are all linked and depend on
Figure 4. MVL-PLA2 affects focal adhesion structure. HMEC-1 cells were allowed to adhere to a fibronectin-coated surface for 48 h, treated or
not (control) with 100 nM MVL-PLA2. After permeabilization, cells were co-stained for avb3 integrin with LM609 antibody and Alexa fluor 488-
conjugated secondary antibody (green), and for actin with TRITC-conjugated phalloidin (red). Scale bars: 10 mm (a, b, c) and 4 mm (d, e, f).
doi:10.1371/journal.pone.0010124.g004
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reorganization of the cytoskeleton. Directed cell migration requires
that cell-generated traction stresses exerted on the ECM are
spatially and temporally coordinated [37]. Traction stresses are
thought to originate in the actin cytoskeleton and be transmitted to
the ECM through FA [28]. We show here that MVL-PLA2
induces a reduction in the size of FAs and their redistribution all
over the ventral surface of cells. MVL-PLA2 also impedes integrin
avb3 clustering and its localization in lamellipodia. These results
are in concordance with the work of Castel et al. [38], showing that
treatment of M21 melanoma cells with av integrin antagonists,
notably RGD-peptides, disrupts the actin cytoskeleton, redistrib-
utes av integrins and induces molecular disassembly of focal
contacts.
Cell motility is the result of a complex series of events that must
be integrated both spatially and temporally [39]. Efficient motility
requires the coordinated regulation of actin, MTs, and adhesion
sites throughout the migration process [37]. Incorporation of
EGFP-tagged a tubulin into MTs allows the tracking of individual
MT plus ends and the analysis of MT dynamics. Interestingly, we
found that treatment with native or enzymatically inactivated
MVL-PLA2, dramatically increased MT dynamicity in HMEC-1
cells. To our knowledge, this is the first report describing the effects
of a secreted PLA2 on MT dynamics. Microtubule targeting
agents are known to have anti-angiogenic effects through
modulation of MT dynamicity (for review see [40]). MTs are
essential in the orchestration of endothelial cell motility [41,42]. It
is thus likely that the specific mechanism of action of MVL-PLA2
(i.e., interference with cytoskeleton dynamics) is responsible for
inhibition of the angiogenic process.
Cells treated with MVL-PLA2 presented a disorganized F-actin
and lost their migrating shape. Actin stress fibers are clearly visible
in migrating cells but are thinner or absent in MVL-PLA2-treated-
cells. In this case, we observed the development of circumferential
actin bundles instead of straight fibers (see Fig. 4B). Pletjushkina et
al. have reported the same observation in rat fibroblasts after
treatment with paclitaxel [43], suggesting that MT dynamics is
required for actin polymerization. Furthermore, it has been
recently reported that alteration of MT dynamics is associated
with changes in actin cytoskeleton and defective FA assembly in
endothelial and breast carcinoma cells [41,42].
The mechanism of action of MVL-PLA2 on MT dynamics
remains unknown. However, it has long been known that MTs
control local activation of Rho GTPases, Rac and Cdc42, and that
alteration of MT dynamics leads to a depolarized morphology and
to an inhibition of directional migration [44]. On the other hand,
it has been proposed that Rac, transiently activated by new
integrin binding, selectively stabilizes MTs toward the front of the
cell. Since MTs target FAs to accelerate their turnover, this could
Figure 5. MVL-PLA2 increases microtubule dynamics in living HMEC-1. (A) Time-lapse sequence of video frames of the plus ends of several
MTs in a control cell (top panels) or in a cell treated with 100 nM MVL-PLA2 (bottom panels). Arrowheads indicate one MT end for which the position
did not change over a period of 24 s. in the control cell and one MT that underwent a shortening event in the treated cell. Time is indicated in
seconds (0). Scale bar: 10 mm. (B) Life history plots of the length changes of 3 representative MTs in living HMEC-1 cells treated or not (control) with
100 nM of MVL-PLA2 as described in experimental procedure section. In the presence of 100 nM of MVL-PLA2, MTs are characterized by more
extensive growth and shortening events compared with control cells.
doi:10.1371/journal.pone.0010124.g005
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favor new adhesion formation at the leading edge of the cell [45].
Furthermore, it was recently shown that RhoA-mDia1 signaling
regulates MT dynamics, FA formation, and the organization of the
lamellipodial actin network [42]. Based on our data, we propose
that the observed increase in MT dynamics in MVL-PLA2-treated
cells could affect cell polarization and the turnover of FAs, leading
to the impairment of directional migration. We are aware that this
proposal remains speculative and future studies will thus be carried
out to check whether MVL-PLA2 interferes with Rho GTPases
signaling cascade.
We demonstrate here that MVL-PLA2 abolishes in vitro and in
vivo angiogenesis through inhibition of a5b1 and av integrins
function. In addition, we report original findings on the anti-
angiogenic mechanism of MVL-PLA2 and demonstrate that
treatment of endothelial cells with MVL-PLA2 results in an
increase in MT dynamics, a disorganization of the F-actin network
and alterations in FA formation. Further studies should be carried
out to completely unveil the anti-angiogenic mechanism of MVL-
PLA2. Nevertheless, MVL-PLA2 could represent a new po-
tential integrin antagonist for anti-angiogenic and anti-metastatic
therapy.
Supporting Information
Figure S1 MVL-PLA2 does not significantly affect HMEC-1
viability. (A) HMEC-1 cells, seeded in 96-well plates, were treated
with various concentrations of MVL-PLA2 for 72 h. After
incubation 3 hours with 0.5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), the stain was eluted with
100 IˆJl DMSO and absorbance was measured at 550 nm. (B)
Suspended HMEC-1 cells (0.56106 cells/ml) were treated with
various concentrations of MVL-PLA2 for 30 min A˜ room
temperature. The LDH activity released by damaged cells was
measured by a colorimetric assay on 80 Aˆml of clarified
supernatant. Total release of LDH (100% toxicity) was obtained
in the presence of 0.1% Triton-X100 in the medium (TX100).
Found at: doi:10.1371/journal.pone.0010124.s001 (0.54 MB TIF)
Figure S2 MVL-PLA2 alter the size and the cell distribution of
FA HMEC-1 cells were treated or not with 100 nM MVL-PLA2,
permeabilized and co-stained for paxillin with anti-paxillin
antibody (green) and for actin with TRITC-conjugated phalloidin
(red). Scale bars: 10 Aˆmm.
Found at: doi:10.1371/journal.pone.0010124.s002 (9.97 MB TIF)
Video S1 HMEC-1 cells expressing GFP-tubulin were treated
without MVL-PLA2 for 1 h and observed using the 6100
objective lens of an inverted fluorescence microscope (Leica).
Thirty-one images per cell were acquired at 4-second intervals
using a digital camera driven by Metamorph software as
previously described (Pourroy et al. (2006) Cancer Res 66:
3256).
Found at: doi:10.1371/journal.pone.0010124.s003 (8.41 MB ZIP)
Video S2 Microtubule dynamics in MVL-PLA2-treated
HMEC-1 cells. HMEC-1 cells expressing GFP-tubulin were
treated with 100 nM MVL-PLA2 for 1 h and observed using the
6100 objective lens of an inverted fluorescence microscope
(Leica). Thirty-one images per cell were acquired at 4-second
intervals using a digital camera driven by Metamorph software as
previously described (Pourroy et al. (2006) Cancer Res 66: 3256).
Found at: doi:10.1371/journal.pone.0010124.s004 (8.55 MB ZIP)
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Table 1. Effects of MVL-PLA2 on the variables of microtubule dynamic instability in living HMEC-1 cells.
Variables Control 100 nM MVL-PLA2 % change
100 nM BPB-inactivated
MVL-PLA2 % change
% of dynamic microtubules 58.564.0% 78.164.1% ** 76.767.4% *
Rate (mm/min) G 7.1260.29 9.3560.36 +31% *** 7.7160.50 NS
S 8.7960.38 9.9260.45 +13% ** 12.5460.83 +43% ***
Length (mm) G 1.0660.03 1.0360.04 NS 1.3460.07 +26% ***
S 1.3260.05 1.2960.06 NS 1.8160.13 +37% ***
Duration (min) G 0.14960.008 0.11060.004 226% *** 0.17460.012 NS
S 0.15060.006 0.13060.006 213% * 0.14560.008 NS
P 0.31560.015 0.24760.013 222% *** 0.23860.019 224% **
% time spent G
S
P
15.4
21.5
63.1
18.7
24.9
56.4
27
19.5
53.4
Transition frequency (min21) C 2.2560.26 2.6360.17 NS 2.1560.30 NS
R 6.4860.35 7.7560.42 +20% * 6.4860.62 NS
Transition frequency (mm-1) C 1.7460.16 1.4860.14 NS 1.1860.21 232% *
R 0.8860.04 1.0160.05 NS 0.6460.08 227% **
Dynamicity (mm/min) 3.0 4.2 +40% 4.5 +50%
Variables of microtubule dynamic instability were determined on living HMEC-1 cells after 1 h incubation with 100 nM native or BPB-inactivated MVL-PLA2. G: growth; S:
shortening; P: pause; C: catastrophe; R: rescue; NS: non significant.
Student’s t test: * p,0.05; ** p,0.01; *** p,0.001.
doi:10.1371/journal.pone.0010124.t001
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